Loading...
01/09 23:13
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals financial struggles, with declining sales, EBITA, and EPS, alongside increased expenses and liabilities. The Q&A section highlights inflationary pressures, integration risks, and geopolitical uncertainties. Despite stable gross profit and a proposed dividend, the lack of a share buyback program and divestment risks further dampen sentiment. The cautious outlook on pricing, competition in specialties, and unclear management responses suggest challenges ahead. Overall, the negative financial performance and risk factors outweigh the positive aspects, leading to a negative prediction for stock price movement.
Sales EUR 16,200,000,000, a decline of 3% year-over-year due to geopolitical challenges and pressure on industrial chemical selling prices.
Operating Gross Profit EUR 4,030,000,000, stable compared to last year, with a slight increase in gross profit as a percentage of sales despite lower gross profit per unit.
Operating EBITA EUR 1,100,000,000, a decline of 13% year-over-year, impacted by inflationary costs and lower gross profit per unit.
Free Cash Flow EUR 893,000,000, down from EUR 1,700,000,000 in 2023, due to a decline in operating EBITDA and a slight outflow of working capital.
Earnings Per Share EUR 3.71, compared to EUR 4.73 last year, affected by the sale of Raj Petro Specialties and other special items.
Operating Expenses EUR 2,600,000,000, an increase of 4.7% year-over-year, driven by inflation and higher personnel expenses.
Return on Capital Employed (ROCE) 14%, down from 17.7% in 2023, with ROCE before special items at 15.6%, down from 18.9%.
Net Financial Liabilities EUR 2,800,000,000, an increase due to lower cash from operations and cash outflow for acquisitions.
Leverage Ratio (Net Debt to Operating EBITDA) 1.9 times, indicating a stable financial position despite increased liabilities.
New Product Launch: Brentag's innovative CO2 explorer won the ICES Best Digital Innovation Award 2024, allowing companies to assess and manage their carbon footprint more effectively.
Market Expansion: Brentag closed eight acquisitions with an enterprise value of around €550,000,000 in 2024, enhancing its industry segments in specialties and essentials.
Operational Efficiency: Brentag's cost containment program aims for a cost reduction of EUR 300,000,000 per year by 2027, with a targeted cost out impact of EUR 100,000,000 for 2025.
Site Optimization: Brentag closed 33 locations in 2024 as part of its site network optimization.
Strategic Shift: Brentag is focusing on the disentanglement of its two divisions to enhance value creation and differentiation potential.
Divestment Strategy: Brentag sold Raj Petro Specialties in India to improve its business portfolio, indicating a strategic shift towards core distribution business.
Economic and Political Uncertainty: The company faces high economic and political uncertainty, which is expected to impact global economic growth and the business environment in 2025.
Competitive Pressures: The highly competitive business environment has led to sustained pressure on industrial chemical selling prices, affecting gross profit per unit.
Supply Chain Challenges: The company experienced extended bottlenecks in the industry cycle, impacting sales and operational efficiency.
Cost Containment Measures: The company is implementing a cost containment program aiming for EUR 300 million in annual savings by 2027, with one-off costs expected to be around EUR 300 million.
Inflationary Pressures: Inflation has driven higher volume-related costs, impacting the overall bottom line results.
Divestment Risks: The sale of non-core assets, such as Raj Petro Specialties, has led to a loss of around EUR 42 million, indicating risks associated with divestments.
Acquisition Integration Risks: The company has closed multiple acquisitions, which may pose integration challenges and impact operational performance.
Regulatory Issues: Legal risks related to the sale of certain products in North America have resulted in additional expenses, highlighting regulatory challenges.
Cost Containment Program: Aiming for a cost reduction of EUR 300 million per year by 2027 compared to 2023.
Divisional Strategies Execution: Progress in executing targeted disentanglement of two divisions for value creation.
Acquisitions: Closed eight acquisitions with an enterprise value of around EUR 550 million in 2024.
Sustainability Initiatives: Innovative CO2 explorer won ICES Best Digital Innovation Award 2024.
M&A as Growth Enabler: M&A remains a key strategic pillar for future growth.
2025 Operating EBITA: Expected in the range of EUR 1.1 billion to EUR 1.3 billion.
Volume and Pricing Outlook: Moderate improvements in volumes and slightly better pricing environment expected in 2025.
Cost Out Program: Targeting to double cost savings in 2025 compared to 2024.
Free Cash Flow: Generated EUR 893 million in 2024, down from EUR 1.7 billion in 2023.
Dividend Proposal: Stable dividend proposed for the annual general meeting in May.
Dividend Proposal: Brentag has proposed a stable dividend to the annual general meeting in May, maintaining or increasing the dividend payout for the fourteenth consecutive time.
Share Buyback Program: None
The earnings call reveals financial struggles, with declining sales, EBITA, and EPS, alongside increased expenses and liabilities. The Q&A section highlights inflationary pressures, integration risks, and geopolitical uncertainties. Despite stable gross profit and a proposed dividend, the lack of a share buyback program and divestment risks further dampen sentiment. The cautious outlook on pricing, competition in specialties, and unclear management responses suggest challenges ahead. Overall, the negative financial performance and risk factors outweigh the positive aspects, leading to a negative prediction for stock price movement.
The earnings call highlights strong financial management, with a significant reduction in cash outflow and improved operating efficiency. The transition to in-hospital revenue is progressing well, driving revenue growth. Profitability metrics have been achieved ahead of schedule, and a three-year cash runway provides financial stability. Despite risks from industry turbulence and regulatory costs, the overall sentiment is positive, supported by optimistic guidance and strategic business transition. The lack of negative sentiment in the Q&A session further supports a positive outlook.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
